Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01122888
Other study ID # NCI-2011-01455
Secondary ID NCI-2011-01455CD
Status Terminated
Phase Phase 1
First received January 12, 2010
Last updated April 27, 2015
Start date December 2009
Est. completion date April 2015

Study information

Verified date April 2015
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This clinical trial is studying how well giving cilengitide together with sunitinib malate works in treating patients with advanced solid tumors or glioblastoma multiforme. Cilengitide and sunitinib malate may stop the growth of tumor cells by blocking blood flow to the tumor. Giving cilengitide together with sunitinib malate may kill more tumor cells. Studying samples of blood in the laboratory from patients receiving cilengitide and sunitinib malate may help doctors understand the effect of these drugs on biomarkers.


Description:

PRIMARY OBJECTIVES:

I. Determine the effect of cilengitide on changes in serum VEGFR2, a pharmacodynamic biomarker of sunitinib malate effects on endothelial function, during the withdrawal phase of a course of sunitinib malate in patients with advanced solid tumors or glioblastoma multiforme.

SECONDARY OBJECTIVES:

I. Determine the effect of cilengitide exposure on changes in VEGFR2 over the 14-day interval from the end of sunitinib malate administration to the end of course 1 in these patients.

II. Test the safety and efficacy of this regimen in these patients. III. Develop serum collagen c-telopeptide crosslinks (CTx) as a pharmacodynamic marker for cilengitide.

OUTLINE:

COURSE I: Patients receive oral sunitinib malate on days 1-14 (weeks 1-2). Patients are then randomized to 1 of 2 treatment arms.

ARM I: Patients receive cilengitide IV over 1 hour twice in weeks 3 and 4.

ARM II: Patients do not receive treatment in weeks 3 and 4.

COURSE II: Patients in both arms then receive oral sunitinib malate on days 1-14 and cilengitide IV over 1 hour twice in weeks 3 and 4. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed up periodically.


Recruitment information / eligibility

Status Terminated
Enrollment 41
Est. completion date April 2015
Est. primary completion date September 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed solid tumor or malignant glioblastoma multiforme meeting >= 1 of the following criteria:

- Disease refractory to standard therapy

- No standard therapy exists

- Sunitinib malate monotherapy would be appropriate management

- Measurable disease is not required

- Previously treated brain metastases or primary brain neoplasms allowed provided patient is not receiving concurrent corticosteroids

- Karnofsky performance status 70-100%

- Absolute neutrophil count (ANC) >= 1,500/µL

- White blood cell count (WBC) >= 3,000/µL

- Platelet count >= 100,000/µL

- Hemoglobin >= 9 g/dL

- Total bilirubin normal (unless due to documented Gilbert syndrome)

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times upper limit of normal (ULN) (< 5 times ULN in the presence of liver metastases)

- Creatinine normal OR creatinine clearance >= 60 mL/min

- Serum calcium =< 12.0 mg/dL

- QTc < 500 msec

- Patients with any of the following are allowed provided they have New York Heart Association (NYHA) class I-II cardiac function and undergo a baseline echocardiogram (ECHO)/multiple gated acquisition (MUGA):

- History of class II heart failure and asymptomatic on treatment

- Prior anthracycline exposure

- Previously treated with central thoracic radiotherapy that included the heart in the radiotherapy port

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective barrier contraception

- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib malate

- No concurrent uncontrolled illness including, but not limited to, any of the following:

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- Psychiatric illness and/or social situation that would limit compliance with study requirements

- No pre-existing thyroid abnormality for which thyroid function cannot be maintained in the normal range with medication

- No documented thrombosis (pulmonary embolism or deep vein thrombosis) within the past 6 months

- No known coagulopathy or thrombophilia

- No proven gastric or duodenal ulcer or clinically significant gastrointestinal (GI) blood loss within the past 6 weeks

- No history of central nervous system (CNS) hemorrhage

- No life-threatening bleeding diathesis within the past 6 months

- No history of serious ventricular arrhythmia (i.e., ventricular fibrillation or ventricular tachycardia >= 3 beats in a row) or other significant electrocardiogram (ECG) abnormalities

- No poorly controlled hypertension (i.e., systolic blood pressure (BP) >= 150 mm Hg or diastolic BP >= 100 mm Hg)

- No condition that would impair the ability to swallow and retain sunitinib malate tablets, including any of the following:

- GI tract disease resulting in an inability to take oral medications or a requirement for IV alimentation

- Prior surgical procedures affecting absorption

- Active peptic ulcer disease

- No gastrostomy, jejunostomy, or other forms of enteral tube feeding modalities

- None of the following conditions:

- Serious or non-healing wound or ulcer

- Abdominal fistula, GI perforation, or intra-abdominal abscess within the past 28 days

- Cerebrovascular accident or transient ischemic attack within the past 12 months

- Myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within the past 12 months

- NYHA class III or IV heart failure

- Radiographically or physiologically diagnosed usual interstitial pneumonitis (UIP) or non-specific interstitial pneumonitis (NSIP)

- No bone fracture within the past 12 months

- No other concurrent anticancer agents or therapies

- More than 4 weeks since prior radiotherapy or systemic antineoplastic therapy (6 weeks for nitrosoureas, mitomycin C, or bevacizumab) and recovered

- More than 2 weeks since prior hormone replacement therapy or hormonal contraceptives

- More than 1 month since prior surgery

- At least 7 days since prior and no concurrent CYP3A4 inhibitors

- At least 12 days since prior and no concurrent CYP3A4 inducers

- Prior luteinizing hormone-releasing hormone agonists for hormone-refractory prostate cancer allowed

- Prior antiangiogenic agents (e.g., sorafenib, pazopanib, AZD2171 [cediranib maleate], PTK787 [vatalanib], or VEGF Trap [ziv-aflibercept]) allowed provided there is no disease progression

- No prior cilengitide or sunitinib malate

- No prior bevacizumab

- No other concurrent investigational agents

- No concurrent combination antiretroviral therapy for human immunodeficiency virus (HIV)-positive patients

- No concurrent agents with proarrhythmic potential (e.g., terfenadine, quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide, or flecainide)

- No concurrent palliative radiotherapy

- No other concurrent chemotherapy or biologic agents

- No concurrent medications that may cause QTc prolongation

- No concurrent therapeutic doses of coumarin-derivative anticoagulants (e.g., warfarin)

- Up to 2 mg of daily warfarin for the prophylaxis of thrombosis allowed

- Low-molecular weight heparin allowed provided prothrombin time (PT)/international normalized ratio (INR) =< 1.5

- No concurrent grapefruit juice

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Cilengitide
Given IV
Other:
Clinical Observation
Patients undergo a 2-week rest period
Laboratory Biomarker Analysis
Correlative studies

Locations

Country Name City State
United States University of Chicago Comprehensive Cancer Center Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in serum VEGFR2 Over 14 days from the end of sunitinib to the end of course 1 No
Secondary Comparison of the change in serum VEGFR2 in courses 1 and 2 Compared using a paired t-test. Over 14 days No
Secondary Progression-free survival Estimated using the Kaplan-Meier method. Summarized by type, grade, and attribution and compared using chi-squared tests or Fisher exact tests, as appropriate. Assessed up to 30 days after completion of study treatment No
Secondary Response rate evaluated using RECIST criteria Summarized by type, grade, and attribution and compared using chi-squared tests or Fisher exact tests, as appropriate. Up to 30 days after completion of study treatment No
Secondary Serum type I collagen c-telopeptide crosslink measurements Up to 30 days after completion of study treatment No
Secondary Toxicity rates, graded using the NCI CTCAE version 4.0 Compared using chi-squared tests or Fisher exact tests, as appropriate. Up to 30 days after completion of study treatment Yes
See also
  Status Clinical Trial Phase
Terminated NCT02530502 - Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma Phase 1
Withdrawn NCT02194452 - Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors N/A
Completed NCT00238303 - Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Phase 2
Completed NCT02227901 - Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Phase 1
Completed NCT00049387 - Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Phase 1
Completed NCT02015819 - Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas Phase 1
Active, not recruiting NCT02179086 - Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Phase 2
Recruiting NCT04573140 - A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) Phase 1
Active, not recruiting NCT00823797 - Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma Phase 2
Completed NCT00045565 - Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Phase 1
Completed NCT01977677 - Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Phase 1/Phase 2
Completed NCT01648348 - Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Phase 1/Phase 2
Completed NCT00004262 - Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme Phase 1
Terminated NCT01996527 - 3T MRI Biomarkers of Glioma Treatment Response Early Phase 1
Terminated NCT01575275 - Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme Phase 2
Completed NCT01131234 - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT01119599 - RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Phase 1
Terminated NCT01103375 - Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma Phase 1
Completed NCT00459381 - Pazopanib in Treating Patients With Recurrent Glioblastoma Phase 2
Completed NCT00316849 - Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Phase 1